VA Releases Medical Cannabis Discussion Guidelines for Doctors

What VA Physicians May Discuss

VA doctors are authorized to document a veteran's cannabis use in medical records and discuss potential drug interactions or side effects. The guidance, circulated to VA medical centers in June 2026, clarifies that clinical staff may:

• Record patient-reported cannabis use in electronic health records
• Counsel patients on risks of combining cannabis with prescribed medications
• Discuss research findings on cannabis and specific conditions
• Refer veterans to state-licensed providers outside the VA system for cannabis evaluations

The documents don't authorize VA physicians to complete state medical cannabis registry applications or provide written recommendations that qualify veterans for state programs. On a strict reading, the guidance permits informational discussions but prohibits any action that could be construed as a federal recommendation for a Schedule I substance.

Federal Law Constraints on VA Cannabis Policy

The VA's restrictions stem from the Controlled Substances Act, which classifies cannabis as Schedule I with no accepted medical use. Federal employees, including VA physicians, can't recommend or prescribe Schedule I drugs without risking criminal liability under 21 U.S.C. § 841. The VA has maintained this position since issuing VHA Directive 1315 in 2017, which first acknowledged that veterans' cannabis use wouldn't disqualify them from VA pain management or other services.

The 2026 guidance reaffirms that VA facilities can't dispense cannabis. VA pharmacies can't fill state-issued cannabis recommendations. Veterans who obtain cannabis through state programs do so entirely outside the federal healthcare system. The documents note that 38 U.S.C. § 7402 limits VA providers' scope of practice to treatments recognized under federal law.

For context on the VA's evolving stance, see the CannIntel topic hub on VA Medical Cannabis Policy.

Implications for Veterans in State Medical Cannabis Programs

An estimated 4.8 million veterans live in states with operational medical cannabis programs, but fewer than 12% have discussed cannabis use with their VA providers, according to 2025 VA survey data. The new guidance aims to reduce the gap between veterans' actual cannabis use and clinical documentation, which providers say has created blind spots in treatment planning.

VA providers should ask about cannabis use during routine intake and medication reconciliation. They should document frequency, dosage, and delivery method when patients disclose use. They should flag potential contraindications with opioids, benzodiazepines, or anticoagulants.

The guidance doesn't address whether veterans can be denied organ transplants or other procedures based on cannabis use, a question that remains unresolved in several VA regions. It also doesn't clarify whether veterans can use CBD products derived from hemp, which are legal under the 2018 Farm Bill but subject to varying VA facility policies.

The practical effect: veterans seeking state medical cannabis cards must still obtain recommendations from non-VA physicians, typically at out-of-pocket cost. The VA won't reimburse these consultations or the cost of cannabis products.